JohnC.ReneauMD

Clinical Trials

• Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma Start of enrollment: 2022 May 06

  Recruiting

  Phase 1

  Roles: Contact, Sponsor-Investigator, Principal Investigator

• Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Start of enrollment: 2020 Sep 15

  Active, not recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2018 Mar 16

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator, Sponsor-Investigator

• Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms Start of enrollment: 2023 Mar 29

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia Start of enrollment: 2023 May 03

  Recruiting

  Phase 2

  Roles: Principal Investigator, Sponsor-Investigator

• Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia Start of enrollment: 2022 Jun 29

  Recruiting

  Phase 1, Phase 2

  Roles: Contact, Principal Investigator, Sponsor-Investigator

• Join now to see all